Revolution Medicines increases CEO Mark Goldsmith's change-in-control severance to 2x salary plus bonus

Revolution Medicines, Inc.

Severance multiplier raised from 1.5x to 2x for CEO Mark Goldsmith upon qualifying termination near a change in control.
Applies to termination without cause or resignation for good reason from 3 months before to 18 months after a change in control.
Amendment approved by Compensation Committee on June 8, 2022, and executed on June 10, 2022.
Lump sum cash payment equals 2x annual base salary plus target annual bonus.
No other terms of the employment agreement were changed.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.